About us

Supporting clinical trials and orphan drug developers with regulatory affairs and EU legal representation.

IDEA specialises in providing pharmaceutical and biotech developers with Regulatory Affairs and EU legal representation for clinical trials and orphan drug designations (ODD). We offer a range of Regulatory Affairs services to help our clients understand and comply with clinical trial regulations and help ensure a smooth path to Marketing Authorisation Approval.

Our clients include:

  • Niche (orphan) drug developers looking to gain ODD in the USA and Europe
  • Clinicians looking to ensure trial data is valid and appropriately covered
  • Investors seeking to maximize the market opportunity of new molecules
  • CRO’s who know the importance of determining suitable liability and trial subject insurance to cover human trials in Europe.

IDEA’s expert regulatory services range from the provision of stand-alone representative services for an Orphan Drug Designation (ODD) to the design and implementation of a full global regulatory and market access strategy. We are experts at the preparation and review of Regulatory Submissions, including Clinical Trial Authorisation applications and substantial amendments, Orphan Drug Designation applications to the EMA, and parallel submissions to the US FDA, Briefing Packages for Scientific Advice Procedures, Paediatric Investigation Plan (PIP) Applications and Waivers, and Annual Regulatory Reports.


Tamsyn Frost

Tamsyn studied applied biological sciences in the United Kingdom and has over eight years’ experience in regulatory affairs and quality management for clinical trials and orphan drug development. Her experience also includes reproductive toxicology, project coordination and business development.


Dr. Francisco Harrison

Dr. Francisco Harrison is an MD, HBS OPM34 who built the global CRO company, Harrison Clinical Research.  He studied medicine in Spain, the United Kingdom and Germany (Neuropharmacology), has published 60+ articles in professional and scientific journals, and presented in various scientific societies globally.

Copyright IDEA Regulatory 2014 - 2019. All rights reserved.